Market Overview

UPDATE: Piper Jaffray Initiates Galena Biopharma at Overweight on ImmunoRx Potential

Related GALE
Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline
Mid-Afternoon Market Update: Dow Tumbles Over 300 Points; Uniqure Shares Gain Following Release Of Clinical Trial Data

Piper Jaffray initiated coverage on Galena Biopharma (NASDAQ: GALE) with an Overweight rating and a $2.50 price target.

Piper Jaffray commented, "Galena is a cancer immunotherapy company that is developing NeuVax, which could be a new blockbuster breast cancer adjuvant therapy. Galena should complete enrollment of the Phase III PRESENT trial this summer with 36-month Disease Free Survival (DFS) data in mid-2016. Galena is also developing a Folate Binding Protein E39 (FBP-E39) targeted vaccine in a Phase I/II ovarian and endometrial cancer trial with preliminary data at ASCO in June. We look for clinical progress and potential partnerships to drive shareholder value in 2013. Galena recently raised $24 million, which should fund the company into 2014."

Galena Biopharma closed at $1.55 on Friday.

Latest Ratings for GALE

Dec 2015Cantor FitzgeraldUpgradesSellHold
Nov 2015OppenheimerUpgradesPerformOutperform
Sep 2015Raymond JamesInitiates Coverage onOutperform

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (GALE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters